You are here

Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk

Last updated on November 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Erectile Dysfunction
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- CV risk factors

- Male above 18

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Non-informed consent

NCT00874185
Pfizer
Completed
Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief TitleSatisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk
Official TitleSatisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.
Brief SummaryEvaluate satisfaction in people treated with IPDE5 inhibitors over time
Detailed Description12 first patients that are eligible
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationPeople with cv risk
ConditionErectile Dysfunction
InterventionNot Provided
Study Groups/CohortsQuestionnaire
filling in questionnaires
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: June 7, 2011)
720
Original Actual Enrollment
 (submitted: April 1, 2009)
572
Actual Study Completion DateMay 2008
Actual Primary Completion DateMay 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • CV risk factors
  • Male above 18

Exclusion Criteria:

  • Non-informed consent
Sex/Gender
Sexes Eligible for Study:Male
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesNot Provided
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00874185
Other Study ID NumbersA1481256
A1481256
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateFebruary 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now